Broader NICE recommendation for GSK’s Jemperli

UK pharma major GSK (LSE: GSK) has announced that the National Institute for Health and Care Excellence (NICE) has issued final guidance recommending the use of Jemperli (dostarlimab) with platinum-based chemotherapy for first-line treatment of primary advanced or recurrent endometrial cancer with mismatch repair proficiency or microsatellite stability.

The guidance broadens the previous NICE recommendation for dostarlimab across England, with more patients living with primary advanced or recurrent endometrial cancer now potentially eligible for the PD-1-blocking antibody as a first-line treatment option.

Previously, it was recommended alongside platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.